Trump aims at Europe with new drug price regulation
Donald Trump sharply criticized the European Union, calling it "worse than China." The former U.S. President announced a new regulation to lower drug prices in the United States.
Main information
- Donald Trump compared the European Union to China, claiming it is "worse."
- The former U.S. President signed a regulation aimed at reducing drug prices.
- Robert F. Kennedy Jr. supported Trump's criticism of Europe.
Donald Trump, the former U.S. President, strongly criticized the European Union (EU), claiming that it is "in many aspects worse than China." His statement was made during the announcement of a decision to lower drug prices in the United States. Trump emphasized that the EU treats the U.S. unfairly, selling them millions of cars while American exports to Europe are minimal.
Trump signed a regulation that imposes a 30-day deadline to lower prescription drug costs in the U.S. If manufacturers do not comply with the new requirements, the federal government will take further steps. Trump stressed that the United States will no longer subsidize healthcare in other countries that pay significantly less for the same drugs.
European Union has been brutal, brutal. And the drug companies actually told me stories which is just brutal how they forced them. European Union suing all our companies – Apple, Google, Meta – they’re suing all of our companies. They have judges that are European Union-centric and they get rewarded $15billion, $17billion, $20billion, and they use that to run their operation. Not going to happen any longer, that I can tell you, said the American leader, quoted by the "Metro" service.
Reactions to Europe's criticism
Robert F. Kennedy Jr., the Secretary of Health and Human Services, supported Trump's criticism of Europe. He pointed out that the U.S., despite constituting only 4.2 percent of the world's population, generates 75 percent of pharmaceutical companies' revenues. Kennedy emphasized that Europeans pay significantly less for drugs, which is disadvantageous for the American market.
Trump's statements may affect trade relations between the U.S. and the EU. The European Commission expressed satisfaction with the U.S.-China trade agreement but is analyzing its potential implications for EU interests. Meanwhile, the American pharmaceutical lobby has expressed concerns that Trump's policy may increase the U.S.'s dependence on China for innovative drugs.
